Covid-19: Aspen Pharmacare eyes Serum Institute model as it seeks licence to make JnJ vaccine
Johannesburg: South Africa's Aspen Pharmacare wants to model itself on India's Serum Institute by getting a licence to manufacture Johnson & Johnson's (J&J) COVID-19 vaccine, Aspen Chief Executive Stephen Saad said on Thursday.
"At the moment, J&J could take all the product we make because it's their product, and sell it to Europe, for example, sell it to the U.S. or Korea, wherever they choose to. We have no say in that," he told Reuters.
Read also: Reliance Life Sciences gets DCGI approval for COVID vaccine trial
"It's like Serum where they get the licences to manufacture. It's not a foreign model and it's very exciting," he said on the licensing talks.
Read also: Second dose provides strong boost against Covid-19: JnJ
Next Story